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In effector T and B cells immune receptor signals induce within minutes a rise of intracellular Ca++, the activation of
the phosphatase calcineurin and the translocation of NFAT transcription factors from cytosol to nucleus. In addition
to this first wave of NFAT activation, in a second step the occurrence of NFATc1/αA, a short isoform of NFATc1, is
strongly induced. Upon primary stimulation of lymphocytes the induction of NFATc1/αA takes place during the G1
phase of cell cycle. Due to an auto-regulatory feedback circuit high levels of NFATc1/αA are kept constant during
persistent immune receptor stimulation. Contrary to NFATc2 and further NFATc proteins which dampen lymphocyte
proliferation, induce anergy and enhance activation induced cell death (AICD), NFATc1/αA supports antigen-
mediated proliferation and protects lymphocytes against rapid AICD. Whereas high concentrations of NFATc1/αA
can also lead to apoptosis, in collaboration with NF-κB-inducing co-stimulatory signals they support the survival of
mature lymphocytes in late phases after their activation. However, if dysregulated, NFATc1/αA appears to contribute
to lymphoma genesis and – as we assume – to further disorders of the lymphoid system. While the molecular
details of NFATc1/αA action and its contribution to lymphoid disorders have to be investigated, NFATc1/αA differs
in its generation and function markedly from all the other NFAT proteins which are expressed in lymphoid cells.
Therefore, it represents a prime target for causal therapies of immune disorders in future.
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The five members of the family of NFAT transcription
factors are characterized by an evolutionary conserved
DNA binding domain of approximately 300 amino acid
(aa) residues. This domain forms a three dimensional
structure similar to the DNA binding domain of Rel/NF-
κB factors and, therefore, was designated as Rel Similar-
ity Domain (RSD) or Rel Homology Domain (RHD)[1-3].
While the most distantly related NFAT5 shares 41-45%
sequence similarity in its RSD with those of genuine
NFATc factors NFATc1, c2, c3 and c4, the latter exhibit
68-75% sequence homology between their RSDs [4]. The
DNA core motif for the DNA binding of NFAT factors,
A/T GGAAA, resembles one half-site of κB motif of NF-
κB factors, and there is a subset of κB binding motifs to
which NFAT factors can also bind [5,6]. This was shown* Correspondence: serfling.e@mail.uni-wuerzburg.de
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reproduction in any medium, provided the orat the molecular level for the binding of NFATc2 homo-
dimers to the κB motifs within the HIV LTR and the Il8
promoter which share the core motif of NFAT binding
sites [7,8]. Since NFAT and NF-κB proteins contact iden-
tical nucleotides, it is unlikely that both factors can bind
at the same time to the same motif. Instead, they appear
to compete for DNA binding. This seems to depend on
the cellular concentration of both types of factors and
other parameters, such as the level of co-factors, as AP-
1, which affects the binding of NFATs to DNA.
Due to the control by the Ca++/calmodulin-dependent
Ser/Thr-protein phosphatase calcineurin (CN; also
known as PP2B) [1-3], the four genuine NFATc proteins
constitute an own family of transcription factors with in-
dividual properties. Although they were described first
for human Jurkat leukemic T cells [9] and murine EL-4
thymoma cells [10], they are not only expressed in lym-
phocytes but also in numerous other cells of the
hematopoietic system, and also in cardiomyocytes,
muscle, bone and brain cells. While in numerous studiesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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these tissues, in greatest detail the expression and func-
tion of individual NFATc proteins (including their iso-
forms) has been analysed in lymphoid cells [1-3].
In lymphocytes the three NFATc proteins NFATc1
(also known as NFAT2 or NFATc), c2 (NFAT1 or
NFATp) and c3 (NFAT4 or NFATx) are expressed. In-
activation of individual Nfatc genes in mice revealed first
indications for a functional dichotomy between the three
proteins. Whereas due to defects in differentiation of
embryonic heart, inactivation of the Nfatc1 gene led to
the early death of mouse embryos around day 14/15
upon gestation [11,12], Nfatc2−/− mice were born at the
normal Mendelian ratio and did not show any abnormal-
ities within the first weeks upon birth [13-15]. However,
with age Nfatc2−/− mice developed a hyper proliferative
syndrome and elevated primary and secondary immune
responses. Due to delayed apoptosis, Nfatc2−/− mice of
6 months and older harbour at least twofold more per-
ipheral lymphocytes suggesting a suppressive role for
NFATc2 in the generation of effector lymphocytes
[13,14,16]. Several properties of Nfatc2−/− mice were
found to be markedly enhanced in mice double-deficient
for NFATc2 and c3 [17]. Those mice showed a hyper
proliferation of peripheral T and B cells leading to
massive splenomegaly, a tendency to generate Th2 cells
and, thereby, an enormous increase in production of
Th2-type lymphokines [18]. In addition, lymphocytes
double-deficient for NFATc2 and c3 show a strong de-
crease in Fas ligand expression and resistance to apop-
tosis [17,19]. Nfatc3−/− mice, on the other hand, showed
a 50% reduction in number of peripheral T lymphocytes
which might be due to an increase in apoptosis rate. On
the other hand, no obvious defects were observed in
lymphokine (IL-2, IL-4 and IFNγ) production, and a
slight decrease was detected in generation of single posi-
tive (SP) CD4+ and CD8+ thymocytes [20]. When condi-
tionally inactivated in early double-negative (DN)
thymocytes (in Nfatc3fl/fl + lck-Cre mice), obvious defects
were detected at the level of DN3 and double-positive
(DP) thymocytes stages implying a role for NFATc3 in β
selection and positive selection of thymocytes [21].
Contrary to peripheral lymphocytes from NFATc2 and
c3-deficient mice, Nfatc1−/− lymphocytes from mice gen-
erated by complementation of Rag−/− blastocytes with
Nfatc1−/− embryonic stem cells showed a marked de-
crease in proliferation upon immune receptor stimula-
tion [22,23]. This became obvious upon challenging
Nfatc1−/− T cells with αCD3 (+αCD28), concanavalin A
or PMA+ ionomycin, while no difference in their IL-2
synthesis was detected [22]. In distinct contrast to
NFATc2 + c3-double-deficient T cells, Nfatc1−/− effector
T cells produced markedly less – and not more - IL-4
(and IL-6) upon αCD3 stimulation than T cells from wildtype mice [22,23], and αIgM stimulation revealed a de-
crease in BCR-mediated proliferation capacity of Nfatc1−/−
splenic B cells [22]. Similar results were observed upon
conditional ablation of NFATc1 in B cells [24]. While in
such Nfatc1fl/fl +mb1-Cre (or Cd23-Cre) mice, splenic B
cell development appeared to be normal, in agreement
with earlier observations [25] a 5–10 fold reduction in
peritoneal B1a cells was observed. In addition to their low
proliferation rate upon BCR stimulation, Nfatc1−/− splenic
B cells showed a decrease in their capacity to stimulate T
cells and an increase in AICD and IL-10 production.
Moreover, a mild clinical course of Experimental Auto-
immune Encephalomyelitis (EAE) was observed for
Nfatc1fl/fl +mb1-Cre mice. Several of these defects appeared
to be due to the diminished Ca++ flux in Nfatc1−/− B cells
whose proliferation is controlled by persistent Ca++/CN sig-
nals [24].The Ca++/calcineurin-mediated induction of NFATs
in lymphocytes
NFATc factors differ from most other transcription factors
by their strict dependency on Ca++ signals and CN activity
[26] which induce the nuclear translocation and, thereby,
activation of NFATc proteins. In the cytosol of effector
lymphocytes and of most T and B cell lines, NFATc pro-
teins are heavily phosphorylated and appear to be in com-
plexes with the non-coding RNA NRON (Nonconding
[RNA] repressor of NFAT) [27]. NRON creates a platform
for larger RNP complexes [28] containing, in addition to
NFAT, the three NFAT kinases casein kinase 1 (CK1),
glycogen synthase kinase 3 (GSK3) and dual specificity
tyrosine phosphorylation regulated kinase (DYRK), and
calmodulin with further proteins [29].
Within minutes, immune receptor triggering leads to a
rise in free intracellular Ca++ by releasing Ca++ from
endoplasmic reticulum (ER) stores and, in particular, the
influx of extracellular Ca++ through calcium-release-
activated calcium (CRAC) channels. The details of this
so-called store-operated calcium entry (SOCE) have been
summarized in several comprehensive reviews to which
we want to refer here [30-32]. Elevated free Ca++ level
results in the binding of Ca++ to calmodulin followed by
the binding of Ca++/calmodulin to CN which interacts
through two “docking” motifs with NFATc proteins [33]
(Figure 1). As a result of dephosphorylation of 13 aa resi-
dues within the regulatory region of NFATc2 [34], the
nuclear localization signal of NFATc2 appears to be
exposed followed by the binding of nuclear import fac-
tors [29] and rapid nuclear translocation. While the
details of this process have yet to be elucidated, all three
NFATc factors expressed in lymphocytes appear to be
induced and translocated into the nucleus of lympho-
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Figure 1 Scheme of the mouse Nfatc1 gene, its inducible promoter P1 (above) and the inducible short isoform NFATc1/αA (below)
(modified according to refs. [35,44,49,50,96]). In the promoter sequence, vertical dashes indicate CpG residues. Binding sites for transcription
factors are shown as filled circles (for Sp1/Sp3 binding) or as boxes for the binding of various other factors. The murine Nfatc1 gene spans
approximately 110 kb DNA and is divided into 11 exons. Its expression is directed by two promoters, P1 and P2, and two poly A addition sites,
pA1 and pA2. For the generation of NFATc1/αA RNA (encoding the α-peptide), the induction of P1 promoter results in the transcription of exon
1, splicing to exon 3 and poly A addition at the poly A site pA1. RNAs encoding the β-isoforms (with the β-peptide encoded by exon 2) are
directed by promoter 2. The sequence of the N-terminal α–peptide from NFATc1/αA is given below. For NFATc1/αA, the Rel Similarity Domain,
RSD, and transactivation domain, TAD-A, are indicated. In analogy to other NFATc factors (see Refs. [1-3]), two sites A and B for the binding of
calcineurin, a nuclear localization signal, NLS, and several Ser-rich motifs that are phosphorylated, are also indicated. Below NFATc1/αA, the aa
sequence of N-terminal α-peptide is shown in which all Pro and Ser/Thr residues are underlined.
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of NFATc1 in lymphocytes
In effector T and B lymphocytes immune receptor sig-
nals exert a secondary effect on NFAT activation, namely
the strong induction of Nfatc1 expression. Contrary to
the Nfatc2 gene which is constitutively expressed in per-
ipheral effector lymphocytes, the transcription of the
Nfatc1 gene is strongly induced upon stimulation in per-
ipheral T and B cells. This results in the predominant
synthesis of the short NFATc1/αA isoform which spans
711 aa in mouse [35]. NFATc1/αA differs from the
longer NFATc proteins by its short C-terminal peptide
(Figure 1 and Table 1). Thereby, it lacks a second trans-
activation/repressor domain which has been described
for the longer NFATc1 isoforms C [36] (spanning 925[NFATc1/βC] and 939 aa [NFATc1/αC], respectively) and
NFATc2 [37]. This domain harbours two highly con-
served sumoylation motifs, and sumoylation of these
motifs in NFATc1/C exerts a “dampening” effect on IL-2
production [38]. In addition, NFATc1/αA whose gener-
ation is directed by the inducible P1 promoter (Figure 1)
differs from the NFATc1 β isoforms and NFATc2 by an
unusual N-terminal peptide – the so-called α-peptide.
The α-peptide spans 42 aa containing 9 Pro and 8 Ser +
Thr residues in murine NFATc1/αA (Figure 1), com-
pared to 1 Pro and 2 Ser +Thr residues in the 28 aa long
N-terminal β peptide of NFATc1/β proteins. When
expressed in EL-4 cells, NFATc1/αA shows a half-life be-
tween 2–4 h, whereas NFATc1/βA appears to be more
stable, in particular upon stimulation of cells by TPA
Table 1 Selected properties of individual murine NFATc proteins expressed in lymphoid cells
NFATc
Proteins
Length1) Induction2) SUMO- Properties Refs.
[aa] RNA/Protein sites3)





NFATc1/βA 703 -/- (1) n.d. [38]
NFATc1/αC 939 +/+/- 2 (+1) pro-apoptotic, (inhibits proliferation) [35,38,39]
NFATc1/βC 925 -/- 2 (+1) n.d. [38]




NFATc3 1076 /- 1-2 (anti-proliferative) [98]
(NFAT4,
NFATx)
1) Data from the NCBI database “Gene”. There, two short NFATc2 versions of 452 and 672 aa are also documented. However, their expression and function are
unknown. For a comprehensive study about human and murine NFATc RNAs see Ref. [47].
2) Induction upon immune receptor stimulation in naïve and Th0/Th1 effector T cells and splenic B cells. RNA data were compiled from RNA Seq (E.S. et al.,
unpubl.) and real time PCR data obtained with splenic T and B cells upon primary stimulation [39]. The protein data reflect the results of Western blot assays [39].
+, 3–5 fold induction; +++, 50 fold induction and more.
3) Existence of SUMO-consensus sites within NFATc proteins. For NFATc1 and c2, their SUMOylation has been demonstrated in vivo [38,97]. (1) for NFATc1
indicates the existence of a “silent” SUMO consensus sites which remains un-used [38]. In NFATc3, two SUMO sites are present but only one corresponds to a
“perfect” site.
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protein, the β-, but not the α-peptide is able to extend
the half-life of the relatively unstable receptor protein in
293 HEK cells [39].
NFATc1/αA is predominantly induced in Th0 and Th1
effector cells, whereas under conditions of T cell anergy,
in regulatory T cells (Treg) and in Th9 and Th17 its in-
duction is suppressed [39]. The suppression in Treg
appears to be due to the binding of Foxp3, the cell
lineage specification factor of Treg [40], to the inducible
Nfatc1 P1 promoter [41]. In conventional CD4+ T cells
the induction of NFATc1/αA can be suppressed by ICER,
an inhibitory short isoform of CREM, which is induced
by high cAMP levels. Treg contain high levels of cAMP
[42], and by direct contacts they elevate cAMP levels in
conventional effector T cells. Thereby, ICER is translo-
cated into the nuclei of effector T cells and binds to the
two cAMP responsive elements (CRE) within the indu-
cible Nfatc1 P1 promoter [43].
In peripheral T and B cells, NFATc1/αA is the most
prominent NFATc1 protein upon immune receptor
stimulation. For the full induction of NFATc1/αA protein
in primary T and B cells more than 24 h activation
through immune receptors are necessary, whereas upon
secondary stimulation of T cells, NFATc1/αA is fully
induced within a few hours [24,36,44]. Triggering of co-
stimulatory receptors, such as ICOS in T cells [45],
enhances the immune receptor-mediated induction of
NFATc1/αA. Since NFATc1/αA is also strongly induced
in T cells double-deficient for NFATc2 and c3 [39], the
induction (and maintenance?) of high NFATc1 levelsdoes not seem to depend on NFATc factors other than
NFATc1 (as on NFATc2, as previously reported [46]).
The identification of Rcan1 and calcineurin Aβ/Ppp3cb
genes as NFATc1 targets in splenic B cells [24] suggests
a regulatory circuit which guarantees persistent high ex-
pression of NFATc1/αA in peripheral lymphocytes upon
antigen challenging by auto-regulation.
The murine and human Nfatc1 genes span approxi-
mately 110 and 140 kb DNA, respectively, and are
divided into 11 exons (Figure 1) (see also Ref. [47] for a
detailed description of human and murine NFATc genes).
The inducible transcription of NFATc1/αA is directed by
the promoter P1 located in front of exon 1. P1 spans ap-
proximately 800 bp which are highly conserved between
mouse and human. Similar to the promoter P2 located
in front of exon 2, the P1 promoter corresponds to a
CpG methylation island and forms a DNase I hypersensi-
tive chromatin site in T cells [35]. In addition, the chro-
matin of the P1 promoter bears a number of epigenetic
chromatin marks, such as H3K4me3 as a typical sign of
active eukaryotic promoters [48]. In human Hodgkin´s
lymphoma cell lines in which the NFATC1 gene is sup-
pressed all CpG residues of P1 were found to be fully
methylated, whereas in Jurkat T cells they are de-
methylated [49].
The P1 promoter can be divided into a proximal and
distal block of homology, each spanning approximately
300 bp DNA. Both DNA blocks contain binding sites for
NFAT factors, and in ChIP assays using EL-4 T cells it
has been shown that they are bound by NFATs in vivo
[39]. The NFAT binding sites within the distal block
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and bind NFAT factors with high affinity in EMSAs
in vitro [35]. Upstream of these repeats, a composite NF-
κB/NFAT motif is located to which NF-κB factors were
bound in EMSAs, but which could also allow the binding
of NFAT homo-dimers. In addition, the P1 promoter
contains two CRE-like sequence motifs located in the
proximal and distal block of homology. They share 100%
sequence homology between mouse and man and were
bound by CREB, Fos and ATF proteins in EMSAs [50].
The binding of CREB might be responsible for the poor
transcriptional activity of the P1 promoter upon αCD3/
CD28 or TPA and ionomycin stimulation in T cells and
the stimulatory effect of cAMP signals on P1 activity
which, on the other hand, do not exert a positive but
suppressive effect on the induction of the chromosomal
Nfatc1 gene in T cells [35]. Whereas fusion of P1 to 5 kb
upstream DNA did not result in a marked increase of its
activity in transient transfections, fusion to a 1 kb DNA
stretch from intron 1 of Nfatc1 gene resulted in a 3–4
fold increase in P1 activity but did not change its induci-
bility [35]. However, when a DNase I-sensitive site from
the last intron of the gene [51] was cloned downstream
of a luciferase reporter gene whose expression was direc-
ted by P1, a 10–20 fold increase in P1-directed luciferase
induction was detected (S. K.-H., unpubl. data).
In addition to P1 promoter activity, the generation of
stable NFATc1/αA RNAs needs poly A addition at the prox-
imal poly A site A1 near the end of exon 9 (Figure 1). For
the human NFATC1 gene, in transfection assays the pA1
site appeared as a “weaker” site than the distal NFATC1
pA2 site or the proximal poly A site from the Ig μ heavy
chain gene [44]. From these and further experiments we
concluded that in naïve and resting peripheral lymphocytes
in which the longer NFATc1 isoforms are predominantly
formed the proximal pA1 site remains unrecognized result-
ing in the generation of long NFATc1 RNAs. Due to the
massive increase in splice/polyadenylation factors in acti-
vated T cells [52] in these cells the pA1 site becomes bound
by polyadenylation factors and, thereby, functionally active
[44]. Surprisingly, the pA1 sites of NFATc1 genes are not
conserved between human and mouse leading to the syn-
thesis of a 4.5 kb long NFATc1/αA RNA in mouse lympho-
cytes, compared to that of 3 kb in human T cells (Ref. [44]
and unpubl. data).
NFATc1/αA is not induced in anergic lymphocytes
The immune system does not only defend the organism
against invading (micro-) organisms but also has to tolerate
self-antigens to avoid auto immune diseases. In thymus, the
majority of auto-reactive thymocytes are eliminated by the
negative selection of DP thymocytes [53]. In addition to this
central tolerance mechanism, in periphery the immune sys-
tem is able to prevent unwanted immune reactions byrendering effector T and B cells unresponsive, or by elimin-
ating auto-reactive lymphocytes. Several peripheral toler-
ance mechanisms can be distinguished, such as the
generation of clonal anergy, adaptive tolerance [54], and the
suppression of conventional CD4+T cells (and B cells) by
Treg [55]. While peripheral tolerance mechanisms have
been studied in numerous experimental settings [54], we
will focus here on experiments in which NFAT factors have
been investigated.
Treatment of T cells for 16 h or more with ionomycin
diminishes their subsequent induction by TCR signalling
without inducing apoptosis. This leads to a strongly
reduced RNA synthesis of lymphokines IL-2, IFNγ,
TNFα and GM-CSF upon secondary stimulation [56], a
typical sign of T cell anergy. When the gene expression
profiles of anergic Th1 cells (clone D5) were determined
a dramatic change in gene expression was detected. By
using DNA microarrays, approximately 5 fold less genes
were identified than after (full) activation with PMA and
ionomycin which had changed their expression 3 fold.
Among those 200 genes about 1/3 was also detected in
primary Th1 cells, including several genes encoding E3
ubiquitin ligases and proteases, such as Itch, Cbl-b and
Grail [56,57]. Remarkably, in Nfatc2-/- T cells which are
more resistant to anergy induction than wild type T cells,
the expression of approximately 35 genes – including E3
ligase genes – was reduced implying a specific role for
NFATc2 in anergy induction. Under anergic conditions
two prominent signalling proteins of TCR signalling,
PLCγ1 and PKC-θ became ubiquitinated by Ca++ signals
and degraded [57]. Those and further findings suggested
that under ionomycin-mediated anergic conditions
NFATc2 only - but not AP-1 (or NF-κB and, probably,
further “stimulating” factors, such as NFATc1/αA) - is
induced and binds to a subset of NFAT target genes,
thereby stimulating the transcription of “anergy genes”.
Within the promoters of Rnf128 (encoding Grail) and
caspase 3 genes (a further anergy-inducing gene) com-
posite NF-κB/NFAT sites were detected to which
NFATc2 homo-dimers were predominantly bound under
anergic conditions. This led to the conclusion that the
expression of a subset of anergy-inducing genes is con-
trolled by NFATc2 homo-dimers [58]. NFATc2 was also
shown to control B cell anergy (or adaptive tolerance) in
MD4ML5 mice (expressing a HEL-specific BCR and
transgenic HEL) [59] which are widely used to study B
cell tolerance induction in vivo [60].
These findings suggest that NFATc factors in general
exert a positive effect on E3 ubiquitin ligase expression
and anergy induction [61]. However, published results and
own experimental data suggest that NFATc1/αA plays an
opposite role in anergy induction. In own experiments, the
BCR-mediated induction of NFATc1/αA was found to be
strongly impaired in anergic B cells from MD4ML5 mice
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was inactivated in mice the expression of NFATc1 was
found to be strongly enhanced upon αCD3 stimulation in
naïve CD4+T cells and Treg [62], and in an oral tolerance
model the nuclear appearance and, therefore, induction of
NFATc1 was suppressed in CD4+T cells upon activation
through their TCR and CD4 molecules [63]. Taken to-
gether, these and further data strongly suggest that con-
trary to NFATc2 (and, probably, the longer, non-induced
NFATc1 isoforms) the inducible NFATc1/αA does not fa-
cilitate T and B cell anergy, but contributes to the optimal
function of the immune system.
NFATc1/αA induction is suppressed in regulatory
T cells
Regulatory T cells (Treg) are generated in thymus as so-
called naturally occurring regulatory T cells, nTreg, and
in periphery as inducible regulatory T cells, iTreg. Both
types of Treg are characterized by the expression of
Foxp3, the constitutive expression of CD25 and the
property to suppress the effector function of immune
cells. Earlier work suggested an important role for Ca++
signals in the generation of nTreg [64]. It was also specu-
lated that by binding near to NFAT sites, Foxp3 sup-
presses NFAT activity and lymphokine promoters [65].
This view found experimental support by studies on the
interplay between Foxp2/3 and NFATc2. Determination of
crystal structures of NFATc2-RSD and Foxp2-FKH
(forkhead) domains formed with the distal NFAT site of the
Il2 promoter (the ARRE2 or Pu-bd motif) suggested that
Foxp3 could replace AP-1 in hetero-complexes formed with
NFATc2 at the Il2 promoter [66]. However, novel investiga-
tions on the interaction of FKH domain from Foxp3 with
NFATc2´s RSD and Pu-bd show that the structure of
Foxp3´s FKH differs from that of FKH domain from Foxp2
[67]. These complexes consist of two RSD, four FKH
domains and two DNA sites which were held together by
one “domain swapped” FKH domain dimer. At Pu-bd, the
FKH domain dimers contact in trans two different cognate
Foxp3 binding sites which overlap. Thereby, the FKH do-
main of Foxp3 bridges two DNA molecules by binding to
two individual Foxp3 sites in solution and brings them to-
gether. Concerning the interaction with NFATc2´s RSD,
there is a larger interface between the RSD and Foxp3´s
FKH domain than with that from Foxp2 suggesting that
Foxp3 “fits better” to NFATc2 than Foxp2 [67].
While these structural analyses suggested that Foxp3
and NFATc2 could form heteromeric complexes in Treg
and control their regulatory function (as proposed in
Ref. [66]), they did not show that such complexes really
exist in nTreg or iTreg in vivo. On the basis of X-ray
crystallography, mutations were introduced into the FKH
domain of Foxp3 which interfere with the interaction of
FKH to the RSD of NFATc2 [66]. Infections of mouseCD4+ T cells with retroviruses expressing such mutant
Foxp3 proteins led to conspicuous defects in Foxp3 and
Treg function. All mutations within Foxp3´s FKH which
impaired the interaction with NFATc2 also impaired the
ability of Foxp3 to suppress Il2 expression, and they
impaired the expression of CD25, GITR, CD103, and, in
particular, of CTLA4 which are all positively regulated
by Foxp3 in Treg. Moreover, in a mouse model of auto-
immune diabetes (the BDC2.5/NOD TCR tg mice [68])
co-transfer of CD4+ T cells expressing Foxp3 mutants
were unable to suppress diabetes induction, whereas cells
expressing wild type Foxp3 were able to suppress [66].
Earlier analyses of NFATc2 and c3-deficient mice indi-
cated that the lack of both NFATc factors in mice did
neither affect the generation of nTreg nor their function
to suppress conventional CD4+ T cells. Instead, these
assays suggested an intrinsic role for NFATc2 and c3 in
CD4+ responder T cells to become suppressed by nTreg
[69]. These data and those discussed above prompted us
to investigate the role of NFATc1 in Treg by studying
mice in which NFATc1 was conditionally deleted in T
cells [70]. However, as in Nfatc2−/−c3−/− T cells, no effect
of NFATc1-deficiency was detected on nTreg formation
and function in Nfatc1fl/fl x Cd4-Cre mice. The same was
observed for T cells deficient for NFATc1 and c2, and
again for T cells from mice double-deficient for NFATc2
and c3. However, when the generation of iTreg was
investigated upon primary αCD3+CD28 stimulation by
incubation with TGFβ+ IL-2 in vitro and in vivo, a re-
duction in iTreg formation was detected for T cells defi-
cient for either NFATc1 or c2, and this reduction was
strongly accelerated for T cells double-deficient for
NFATc1 and c2, or NFATc2 and c3. Similarly, the gener-
ation of iTreg was strongly diminished when NFATc1/
c2-double deficient T cells – instead of wild type T cells -
were co-transferred into lymphopenic mice to induce
colitis (which is an approach to induce iTreg under in-
flammatory conditions [71]). In ChIP assays an increase
in NFATc1 binding was detected upon TGFβ treatment
of CD4+ T cells to the intronic CNS1 enhancer element
of the Foxp3 gene whose activity was shown to be con-
trolled by NFAT and Smad factors [72]. Foxp3 suppresses
NFATc1 induction by binding to the P1 promoter and
inhibits its activity [41]. In addition, Treg were shown to
have a reduced Ca++ flux [73], CN activity and, thereby,
NFATc activation [74].
NFATc1 suppresses the Activation Induced Cell
Death (AICD) of lymphocytes
Activation Induced Cell Death (AICD) is one route of apop-
tosis induction in lymphocytes which, when suppressed,
contributes to cancerogenesis of lymphocytes and other
cells [75]. NFATc1 and c2 exert contrary effects on AICD of
peripheral B and T cells. Upon α-IgM stimulation murine
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wild type B cells, indicating an anti-apoptotic activity for
NFATc1 and, particularly, for NFATc1/αA which is predom-
inantly expressed under these conditions in splenic B cells
[24]. Under the same conditions Nfatc2−/− B cells were
found to be resistant to apoptosis induction [24] supporting
earlier work on the pro-apoptotic role of NFATc2 in BCR-
mediated apoptosis in human Burkitt´s lymphoma B cells
[76]. Similar results were observed for murine T cells indi-
cating a dichotomy between NFATc1/αA and NFATc2 in
apoptosis induction [35]. The expression of numerous genes
which are known to affect apoptosis are regulated by
NFATc factors in lymphocytes. Such as the promoters/
enhancers of Fas ligand, CD40 ligand, PD-1, light and osteo-
pontin genes [24,77-81], the promoter directing the expres-
sion of short isoform of caspase 8-inhibitor c-Flip in murine
T cells [82] and several others. However, differences in
NFATc1/αA or NFATc2 binding to the promoters/enhan-
cers of these genes have not been observed. Therefore, it
remains to be shown how the apparent contrasting effect of
various NFATc proteins on AICD of lymphocytes is
reflected at the molecular level. The strong induction of
NFATc1/αA upon stimulation of T and B effector cells sup-
ports the speculation that high levels of NFATc1/αA can
protect against AICD whereas low levels are unable to do
so. However, when (naïve) splenic B cells in which large
amounts of NFATc1/αA are generated upon BCR stimula-
tion for 2 days ex vivo [24] are stimulated by α-IgM for
3 days and longer, they die by AICD, unless they are rescued
by α-CD40, LPS or CpG which all induce NF-κB factors.
This suggests that in immune responses NFATc1/αA and
NF-κB factors collaborate in the clonal expansion (and dif-
ferentiation) of lymphocytes. At the end of an immune reac-
tion, the majority of lymphocytes will undergo apoptosis
when they bear an excess of NFATc factors, whereas those
with an “optimal” ratio between NFATc1/αA and NF-κBs
will survive.
NFATc1/αA as a putative oncogene which
supports lymphomagenesis
Similar to the control of apoptosis, NFATc factors appear
to exert dual functions in the generation of lymphoid
and other malignancies. Genome-wide mappings of com-
mon insertion sites (CIS) for oncogenic retroviruses
revealed a preference of insertions into the murine
Nfatc1 and c3 genes. Whereas in total 24 provirus inser-
tions were detected for the Nfatc1 locus and 16 for the
Nfatc3 locus, only two insertions located more than
30 kb 3’ from the Nfatc2 gene were detected, and no
within or near the Nfatc4 gene [83-88]. For the Nfatc1
gene, all 24 proviral insertions were detected either
around its promoter region or within (or very close to)
intron 10, and a similar distribution of insertions sites
was found for the Nfatc3 gene. In hematopoietic cells,several DNase I hypersensitive sites, and in Th1 and Th2
cells the H3K4me3 chromatin mark, a sign for active tran-
scription, were mapped within intron 10 of the Nfatc1
gene [48,51]. These data suggest that oncogenic retro-
viruses insert into the transcriptionally active regions of
Nfatc1 gene to affect its expression.
The identification of common sites for retroviral integra-
tions favours the Nfatc1 and Nfatc3 genes as putative onco-
genes for the generation of lymphoid tumors. However, this
does not exclude that the expression of human NFATC1
gene is switched off in classical Hodgkin´s lymphoma cells
in which BCR signalling is suppressed [49], and NFATc3
can function as a tumor-suppressor for retrovirus-induced
T cell lymphomas [84]. Its pro-apoptotic activity favours,
on the other hand, NFATc2 as a tumor suppressor, and it
has been described as a suppressor of neoplastic changes in
chondrogenesis [89].
Albeit not shown in lymphoid cells, the dual role of
NFATc1/αA and NFATc2 in oncogenesis has been demon-
strated by ectopic expression (of constitutively active [ca]
versions of) both factors in NIH 3 T3 cells [90]. While
caNFATc2 led to cell cycle arrest and apoptosis, over-
expression of caNFATc1/αA led to an increase in prolifera-
tion and cell transformation. Moreover, lack of NFATc2
resulted in an elevated tumor formation induced by the
tumor promoter methylcholanthrene. To a large part, the
differences in oncogenic capacity between caNFATc1 and
c2 could be attributed to the C-terminal peptide of
NFATc2, since removal of the 230 aa long C-terminal pep-
tide from NFATc2 (including its SUMO sites) released its
tumor suppressor phenotype and “converted” NFATc2 to a
NFATc1/αA-like protein [90].
There are several reports on the de-regulation of Ca++/CN-
mediated induction of NFATc1 in human haematopoi-
etic malignancies supporting the former finding on the
“oncogenic nature” of NFATc1 (see refs. [91,92] for
current reviews). For diffuse large B-cell lymphomas
(DLBCL) [93] and pancreatic cancer cells [94] an
NFATc1-directed up-regulation of the MYC gene has
been described which appears to be due to the recruit-
ment of histone acetylases to the MYC promoter [95].
This suggests that NFATc1 might also be involved in
further human lymphomas in which c-Myc is over-
expressed, such as in Burkitt´s lymphomas.
Conclusions
The short NFATc1 protein NFATc1/αA differs in its struc-
ture and function from numerous, if not all other NFAT
proteins. NFATc1/αA lacks a 250 aa residues long C-
terminal peptide with two sumoylation motifs, it contains
a specific N-terminal peptide with several Ser/Thr and Pro
residues, and its synthesis is strongly enhanced in effector
T and B cells by immune receptor signals. Several lines of
evidence indicate that NFATc1/αA contributes – in
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fector lymphocytes. These properties favour NFATc1/αA
as a target for treating disorders of the immune system.
Endnotes
aFor simplicity we use here and in all our other publica-
tions the term “NFAT factors” for members of a family of
transcription factors which share a number of specific
properties, e.g. the induction by calcineurin which de-
phosphorylates an array of phosphorylated sites upon cell
activation. We are aware that the term NFAT (Nuclear Fac-
tor of Activated T Cells) is misleading since these transcrip-
tion factors are expressed in numerous other cell types as
well, and the acronym NFAT indicates the term factor.
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